Navigation Links
Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in 81 Patients with Panic Disorder
Date:4/19/2017

Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in 81 Patients with Panic Disorder

Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial

Nobilis Therapeutics, Inc. announced today the completion and formal registration of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder.

Panic disorder is an anxiety disorder where sufferers experience sudden or extreme fear – a severe panic attack -- with no prior warning. Lifetime prevalence estimates for panic disorder in US adults range from 2.0% to 6.0%.

This disorder is treated with drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) (drugs of first choice) and benzodiazepine tranquilizers (drugs of second choice), but these drugs treat only the symptoms of the disease, have numerous adverse side effects, and in many cases are wholly ineffective.

In contrast to conventional treatments, NBTX-001 is based on xenon, a noble gas that has no known toxicity or adverse reactions at the concentrations used in the study.

“Completion and registration of this landmark study is a significant milestone for Nobilis Therapeutics, which, to our knowledge, is the only company pursuing noble gas-based interventions to treat psychiatric and neurodegenerative disorders,” said Vlad Bogin, MD, FACP, CEO of Nobilis Therapeutics. “We look forward to leveraging the important information gained from this trial to pursue additional indications, such as Post Traumatic Stress Disorder (PTSD).”

In March, 2016, Nobilis Therapeutics entered into an exclusive licensing agreement with Harvard University to utilize its intellectual property for treatment of PTSD. Preclinical animal data covered in the licensed patent was published in a peer reviewed journal. The Company is currently planning to conduct clinical trials in patients with PTSD, a disease with similar molecular pathologies to panic disorder.

“NBTX-001 selectively blocks biological pathways in the brain that are associated with stress, fear, and inflammation. Xenon, its active ingredient, has been widely used for medical imaging at similar concentrations. Given its excellent safety profile, favorable pharmacokinetics, and lack of off-target effects, we believe that NBTX-001 will become an excellent alternative to existing psychiatric drugs,” said Thomas Ichim, Ph.D, Chief Scientific Officer of Nobilis Therapeutics.

The clinical trial was registered in the WHO recognized ISRCTN clinical trials registry.

About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.

Contact:

Vlad Bogin, MD, FACP
3042NW Monte Vista Terrace
Portland, OR 97210
Tel: (971) 229-1679
Email: vbogin(at)nobilistx(dot)com
Website: http://www.nobilistx.com
Twitter: @nobilistx

Read the full story at http://www.prweb.com/releases/2017/04/prweb14254174.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Novira Therapeutics Completes $25 Million Series A Financing
3. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
4. Aratana Therapeutics Adds To Drug Development Team
5. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
8. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... ... May 16, 2017 , ... Zansors has secured a ... electrocardiogram (ECG or EKG) acquisition and monitoring device. This Zansors’ next-generation intellectual property ... directly onto the skin, making them significantly easier to deploy and use. , ...
(Date:5/15/2017)... ... 15, 2017 , ... Tunnell Consulting announced that Julia O’Neill, principal ... of Specifications in Process Validation,” at the Process Validation Summit 2017, May 18 ... leaders from the pharmaceutical and biotech industries to explore processes, strategies and new approaches ...
(Date:5/12/2017)... ANN ARBOR, Mich. , May 12, 2017 /PRNewswire/ ... been selected to present at the 36th annual Michigan ... Investment Forum. GreenMark, a Delaware ... will be presenting to investors in attendance, including more ... to deliver health benefits to society through biobased targeting ...
(Date:5/11/2017)... ... May 11, 2017 , ... The key to unlocking the cause ... Sclerosis (MS) is a neurological disorder that can rob people of their ability to ... own brain cells. MS arises from a genetic tendency towards the disease combined with ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
Breaking Biology News(10 mins):